An Exploratory, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of GDD3898 Topical Gel in Subjects with Sebaceous Hyperplasia
Latest Information Update: 11 Mar 2022
At a glance
- Drugs GDD 3898 (Primary)
- Indications Hyperplasia; Sebaceous gland disorders
- Focus Adverse reactions
- Sponsors Lipidio Pharmaceuticals
Most Recent Events
- 11 Mar 2022 New trial record